Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:43 PM
Ignite Modification Date:
2025-12-24 @ 3:43 PM
NCT ID:
NCT00943592
Eligibility Criteria:
Inclusion Criteria:
* Relapsed or refractory acute myelogenous or lymphoid leukemia
* Chronic myelogenous leukemia in accelerated phase or blast-crisis
* Chronic myelogenous leukemia in second or subsequent chronic phase
* Recurrent or refractory malignant lymphoma or Hodgkin's disease
* Multiple myeloma at high risk for disease recurrence
* Chronic lymphocytic leukemia, relapsed or with poor prognostic features
* Other Myeloproliferative disorder (polycythemia vera, essential thrombocythemia, myelofibrosis) with poor prognostic features
* Myelodysplastic syndromes (including PNH) with \> 5% blasts
* Zubroid performance status \< 2 (See Appendix B)
* Life expectancy is not severely limited by concomitant illness
* Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be evaluated by cardiology or pulmonary prior to enrollment on this protocol
* Calculated Creatinine Clearance \> 50 ml/min
* Serum bilirubin 2.0 mg/dl, SGPT \< 3x upper limit of normal
* No evidence of chronic active hepatitis or cirrhosis
* HIV-negative
* Patient is not pregnant
* Patient or guardian able to sign informed consent
Exclusion Criteria:
* Clinical progression
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT00943592
Study Brief:
Protocol Section:
NCT00943592